Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | TTR | P02766 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 4/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 4/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resveratrol SCHEMBL2300985 | 1.00 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Cis-Resveratrol SCHEMBL1931746 | 1.00 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL17629801 | 1.00 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL15106855 | 1.00 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL19425 | 1.00 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL19426 | 1.00 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL3704258 | 1.00 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL31096991 | 0.97 | PTGS1 (0.95) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL3405900 | 0.97 | PTGS1 (0.95) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL22469907 | 0.97 | PTGS1 (0.95) | PTGS1KDM4ETTRLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244703-A1 | USE OF SCIENTIFICALLY MATCHED PLANT SUPPLEMENTS COMBINED WITH ANTINEOPLASTIC COMPOUNDS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | Brio Ventures, LLC (US) | 2021-08-12 | — | — | US | disclosed |
| US-10280442-B2 | Mutant sucrose phosphorylases with improved glycosylation activity towards polyphenols | UNIVERSITEIT GENT (BE) | 2019-05-07 | — | — | US | disclosed |
| US-20180142276-A1 | MUTANT SUCROSE PHOSPHORYLASES WITH IMPROVED GLYCOSYLATION ACTIVITY TOWARDS POLYPHENOLS | UNIVERSITEIT GENT (BE) | 2018-05-24 | — | — | US | disclosed |
| CN-104892478-A | Selenized resveratrol preparation for treating cancers | SHANGHAI AIQI ECOLOGICAL TECHNOLOGY CO LTD | 2015-09-09 | — | — | CN | disclosed |
| CN-101875600-A | Synthesis method for industrially producing resveratrol | CHENGDU XINJI TECHNOLOGY CO LTD | 2010-11-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280442-B2 | Mutant sucrose phosphorylases with improved glycosylation activity towards polyphenols | MGAM, GALE, BPGM | PTGS1 4221/4885KDM4E 971/4885TTR 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.